Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Sees Significant Increase in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totaling 6,729 shares, a growth of 94.7% from the April 15th total of 3,456 shares. Based on an average trading volume of 14,318 shares, the short-interest ratio is presently 0.5 days.

Jasper Therapeutics Price Performance

Shares of JSPRW traded up $0.00 during mid-day trading on Friday, hitting $0.02. 7,989 shares of the company’s stock were exchanged, compared to its average volume of 20,498. Jasper Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.18. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.06.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.